Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE plans appraisal for Pfizer's Inlyta in RCC where others have failed

This article was originally published in Scrip

Executive Summary

NICE, the health technology appraisal institute for England and Wales, wants to look at Pfizer's Inlyta (axitinib) for treating advanced renal cell carcinoma (RCC) after prior systematic treatment has failed. The drug could face a rocky ride if previous NICE appraisals for second-line RCC options are anything to go by. The institute has so far turned down Bayer's Nexavar (sorafenib), Pfizer's Sutent (sunitinib) and Novartis' Afinitor (everolimus) because of doubts over cost-effectiveness.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016740

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel